Myeloma specialist Dr. Matthew J. Rees, MD, from Mayo Clinic, and colleagues shared their findings at the ASCO 2024 conference in June.
The study revealed that BCMA-directed CAR T cell therapy significantly improves survival outcomes in relapsed myeloma patients compared to antibody-drug conjugates and bispecific antibodies, making it a promising option for patients with limited treatment choices.
BCMA (B-cell maturation antigen) is a protein commonly found on myeloma cells, making it a valuable target for therapies. The study focused on three types of BCMA-targeted treatments:
Each of these therapies represents a new approach to treating myeloma. This study used data available from investigational and commercial medicines.
The study included 385 patients treated at Mayo Clinic from April 2018 to June 2023 with BCMA-targeted therapies. The most relevant findings are:
Multiple treatment options are being tested in relapsed and refractory myeloma patients; these are subgroups of high-risk myeloma features with fewer effective options.
Despite the promising results for CAR-T and bispecific antibodies, patients previously treated with BCMA therapy showed poor outcomes regardless of the treatment used. The median progression-free survival was particularly low for these patients, highlighting the need for further research and the development of more effective treatments.
This study highlights the survival benefits of BCMA-directed CAR T therapy in relapsed myeloma patients. However, high-risk groups remain challenging to treat, indicating a need for ongoing research and new treatment strategies. These findings are a significant step forward in improving outcomes for myeloma patients, and further studies will help refine these therapies for broader application.
You can also actively participate in research by joining the HealthTree Cure Hub community! A platform that powers life-saving research.
If you are interested in participating in or finding a clinical trial and keeping track of your labs and studies all in one place, you can create a free account and safely connect your records!
Source:
Myeloma specialist Dr. Matthew J. Rees, MD, from Mayo Clinic, and colleagues shared their findings at the ASCO 2024 conference in June.
The study revealed that BCMA-directed CAR T cell therapy significantly improves survival outcomes in relapsed myeloma patients compared to antibody-drug conjugates and bispecific antibodies, making it a promising option for patients with limited treatment choices.
BCMA (B-cell maturation antigen) is a protein commonly found on myeloma cells, making it a valuable target for therapies. The study focused on three types of BCMA-targeted treatments:
Each of these therapies represents a new approach to treating myeloma. This study used data available from investigational and commercial medicines.
The study included 385 patients treated at Mayo Clinic from April 2018 to June 2023 with BCMA-targeted therapies. The most relevant findings are:
Multiple treatment options are being tested in relapsed and refractory myeloma patients; these are subgroups of high-risk myeloma features with fewer effective options.
Despite the promising results for CAR-T and bispecific antibodies, patients previously treated with BCMA therapy showed poor outcomes regardless of the treatment used. The median progression-free survival was particularly low for these patients, highlighting the need for further research and the development of more effective treatments.
This study highlights the survival benefits of BCMA-directed CAR T therapy in relapsed myeloma patients. However, high-risk groups remain challenging to treat, indicating a need for ongoing research and new treatment strategies. These findings are a significant step forward in improving outcomes for myeloma patients, and further studies will help refine these therapies for broader application.
You can also actively participate in research by joining the HealthTree Cure Hub community! A platform that powers life-saving research.
If you are interested in participating in or finding a clinical trial and keeping track of your labs and studies all in one place, you can create a free account and safely connect your records!
Source:
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.